Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

15.75 +0.28 (+1.81%)
Streaming Delayed Price Updated: 12:56 PM EST, Dec 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
This Oil Giant Is 'Not Great, Not Bad,' But Jim Cramer Says 'I'm Sticking With My Coterra' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said BP (NYSE: BP) is "not great, not bad." He added, "This whole group is going through a real re-evaluation. 
Via Benzinga
News headline image
Why Aurinia Pharmaceuticals Stock Is Slumping Today ↗
The biotech's premium valuation doesn't seem to be sitting well with investors. 
Via The Motley Fool
News headline image
Aurinia Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Aurinia Pharmaceuticals: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
CORRECTING and REPLACING Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2023 and 2023 American College of Rheumatology Convergence (ACR)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Long Term Phase 3 Data Published in Arthritis & Rheumatology Shows LUPKYNIS® (voclosporin) Preserved Kidney Function Up to Three Years in Lupus Nephritis Patients with No New or Unexpected Adverse Events
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Why Aurinia Pharmaceuticals Stock Is Marching Higher Friday ↗
The biotech's board is exploring strategic alternatives to boost shareholder value. 
Via The Motley Fool
News headline image
Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top... 
Via Benzinga
News headline image
Carnival, SMART Global, Friedman Industries And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 200 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Aurinia Surges As It Explores 'Strategic Alternatives,' Including A Potential Buyout ↗
The company makes a lupus nephritis treatment that could easily bolt onto a suitor, analysts say. 
Via Investor's Business Daily
News headline image
Why Are Aurinia Pharmaceuticals Shares Trading Higher Today ↗
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) initiated an exploration of strategic alternatives, including a potential sale, merger, or  
Via Benzinga
News headline image
Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket ↗
Gainers Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
It's the final day of trading this week and we're starting off with a breakdown of the biggest pre-market stock movers worth watching today! 
Via InvestorPlace
News headline image
Tesla, Nike, Sigilon Therapeutics Among Top Trending Stocks Today ↗
 
Via Benzinga
News headline image
Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Announces 2023 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) For Adults with Active Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.